Phenytoin in End-Stage Renal Disease

Winter M.E. , Tozer T.N. Phenytoin. In: Evans W.E. , Schentag J.J. , Jusko W.J. , eds. Applied pharmacokinetics. Spokane: Applied Therapeutics, Inc. 1986; 493–540.

Barth N.G. , Alvan O. , Borga O. , Sjoqvist F. Two-fold inter-individual variation in plasma protein binding of Phenytoin in patients with epilepsy. Clin Pharmacokinetics 1976; I: 444–52.

Atkinson A.J. , Ambre J.J. Antiepileptic drugs. In: Kaimans and Clarks drug assay. New York: Masson, 1984; 47–53.

Bochner F. , Hooper W.D. , Sutherland J.M. The renal handing of diphenylhydantoin and 5-(p-hydroxp-henyl) 5-phenylhydantoin. Clin Pharmacol Ther 1973; 14: 791–6.

Atkinson A.J. , Shaw J.M. Pharmacokinetic study of a patient with diphenylhydantoin toxicity. Clin Pharmacol Ther 1973; 14: 521–8.

Gugler R. , Shoeman D.W. , Huffman D.H. , Cbhlmia J.B. , Azarnof D.L. Pharmacokinetics of drugs in patients with the nephrotic syndrome. J Clin Invest 1975; 55: 1182–9.

Reidenberg M.M. , Odar-Cederlof I. , Von Bahr C. , Barga O. , Sjoqvist F. Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function. NEJM 1971; 285: 264–7.

Odar-Cederlof I.P. , Lunde P. , Sjoqvist F. Abnormal pharmacokinetics of Phenytoin in a patient with uraemia. Lancet 1970; (2) 831–2.

Boobis S.W. Alteration of plasma albumin in relation to decreased drug binding in uremia. Clin Pharm Ther 1977; 22: 147–53.

Hooper W.D. , Bochner F. , Eadie E.J. Plasma protein binding of diphenylhydantoin. Effects of sex hormones, renal and hepatic disease. Clin Pharm Ther 1974; 15: 276–82.

Lipon D.L. , Wintr M.E. , Tozer T.N. Renal function and therapeutic concentrations of Phenytoin. Neurology 1984; 34: 395–7.

Sheiner L.B. , Tozer T.N. Clinical pharmacokinetics: the use of plasma concentrations of drugs. In: Melmon K.L. , Morreli H.F. , eds. Clinical Pharmacology: Basic principles in therapeutics. New York: Macmillan; 1978: 71–109.